Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA names head of oncology office

Executive Summary

FDA Oncology Division Director Richard Pazdur will head the newly created Office of Oncology Drug Products, effective May 1. The agency announced Pazdur's appointment April 22, nine months after beginning a "national search" for a director (1"The Pink Sheet" July 26, 2004, p. 13). Pazdur has been director of the Oncology Drug Products Division within the Center for Drug Evaluation & Research since September 1999. The new office will consolidate drug, biologic and medical imaging reviews previously handled by three separate offices; the reshuffling is part of broader Office of New Drugs reorganization planned for July...

You may also be interested in...

FDA Oncology Drug Reviews Headed By Justice Under Revised Structure

Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs

FDA Drug Safety Overhaul Will Not Affect Oncologics, Office Director Says

Potential changes to FDA's safety review practices will not affect oncology therapies, Office of Oncology Drug Products Director Richard Pazdur said at the American Society of Clinical Oncology annual meeting in Orlando, Fla. May 14

California Federal Court Rejects Settlement Proposal In Coppertone ‘Mineral-Based’ Sunscreen Case

Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts